Verastem Stock Performance
| VSTM Stock | USD 10.23 0.61 5.63% |
The entity has a beta of 1.81, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Verastem will likely underperform. Verastem right now has a risk of 4.13%. Please validate Verastem value at risk and rate of daily change , to decide if Verastem will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Verastem has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Verastem is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (5.63) | Five Day Return (13.01) | Year To Date Return 23.25 | Ten Year Return (90.64) | All Time Return (92.31) |
Last Split Factor 1:12 | Last Split Date 2023-06-01 |
1 | Verastem, Inc. Sees Large Growth in Short Interest | 01/30/2024 |
2 | Payment of 5530 shares by Christoph Westphal of Verastem subject to Rule 16b-3 | 02/29/2024 |
3 | Disposition of 2083 shares by Michael Kauffman of Verastem at 49.92 subject to Rule 16b-3 | 03/11/2024 |
4 | Verastem Q4 Earnings Snapshot | 03/14/2024 |
5 | Disposition of 273 shares by Brian Stuglik of Verastem at 10.38 subject to Rule 16b-3 | 03/19/2024 |
6 | Disposition of tradable shares by Daniel Calkins of Verastem at 12.02 subject to Rule 16b-3 | 03/25/2024 |
7 | Disposition of 5500 shares by Paterson Dan of Verastem at 22.32 subject to Rule 16b-3 | 03/28/2024 |
8 | Disposition of 3654 shares by Robert Gagnon of Verastem at 0.4 subject to Rule 16b-3 | 04/03/2024 |
9 | Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 04/04/2024 |
10 | Disposition of tradable shares by Daniel Calkins of Verastem at 10.87 subject to Rule 16b-3 | 04/05/2024 |
11 | How Many Verastem, Inc. Shares Do Institutions Own - Yahoo Movies UK | 04/10/2024 |
12 | Verastem Oncology appoints new CMO to lead cancer drug trials | 04/18/2024 |
| Begin Period Cash Flow | 74.9 M |
Verastem |
Verastem Relative Risk vs. Return Landscape
If you would invest 1,063 in Verastem on January 20, 2024 and sell it today you would lose (40.00) from holding Verastem or give up 3.76% of portfolio value over 90 days. Verastem is currently generating 0.0217% in daily expected returns and assumes 4.1308% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than Verastem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Verastem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Verastem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Verastem, and traders can use it to determine the average amount a Verastem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0053
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VSTM |
Estimated Market Risk
| 4.13 actual daily | 36 64% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Verastem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Verastem by adding Verastem to a well-diversified portfolio.
Verastem Fundamentals Growth
Verastem Stock prices reflect investors' perceptions of the future prospects and financial health of Verastem, and Verastem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Verastem Stock performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.47 | ||||
| Current Valuation | 188.55 M | ||||
| Shares Outstanding | 25.31 M | ||||
| Price To Earning | (3.02) X | ||||
| Price To Book | 4.98 X | ||||
| Price To Sales | 30.96 X | ||||
| Gross Profit | 2.6 M | ||||
| EBITDA | (92.02 M) | ||||
| Net Income | (87.37 M) | ||||
| Cash And Equivalents | 94.31 M | ||||
| Cash Per Share | 0.50 X | ||||
| Total Debt | 41.56 M | ||||
| Debt To Equity | 0.50 % | ||||
| Current Ratio | 4.87 X | ||||
| Book Value Per Share | 2.27 X | ||||
| Cash Flow From Operations | (86.46 M) | ||||
| Earnings Per Share | (3.96) X | ||||
| Market Capitalization | 258.9 M | ||||
| Total Asset | 149.72 M | ||||
| Retained Earnings | (824.89 M) | ||||
| Working Capital | 117.3 M | ||||
| Current Asset | 110.84 M | ||||
| Current Liabilities | 10.11 M | ||||
About Verastem Performance
To evaluate Verastem Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Verastem generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Verastem Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Verastem market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Verastem's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -205.3 K | -195.1 K | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.75) | (0.78) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.11) | (1.17) |
Things to note about Verastem performance evaluation
Checking the ongoing alerts about Verastem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Verastem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Verastem had very high historical volatility over the last 90 days | |
| Verastem has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (87.37 M) with profit before overhead, payroll, taxes, and interest of 2.6 M. | |
| Verastem currently holds about 94.31 M in cash with (86.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.5. | |
| Verastem has a frail financial position based on the latest SEC disclosures | |
| Roughly 67.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from investing.com: Verastem Oncology appoints new CMO to lead cancer drug trials |
- Analyzing Verastem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Verastem's stock is overvalued or undervalued compared to its peers.
- Examining Verastem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Verastem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Verastem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Verastem's stock. These opinions can provide insight into Verastem's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Verastem Stock analysis
When running Verastem's price analysis, check to measure Verastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verastem is operating at the current time. Most of Verastem's value examination focuses on studying past and present price action to predict the probability of Verastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verastem's price. Additionally, you may evaluate how the addition of Verastem to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Verastem's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verastem listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.96) | Quarterly Revenue Growth (1.00) | Return On Assets (0.47) | Return On Equity (1.39) |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.